UPLC-QToF-ESI-MS的鉴定和虫杀伤活性
Placide Mahougnan Toklo1,2,3, Géorcelin G Alowanou2, Steven Collins N Wouamba3
1Laboratoire de Pharmacognosie et des Huiles Essentielles, Faculté des Sciences et Techniques, Université d'Abomey-Calavi, 01 BP: 918, Cotonou, Benin.
Heliyon
|June 5, 2023
概括
米特拉基纳内尔米斯 (Mitragyna inermis) 提取物对小反动物的胃肠道寄生虫具有显著的抗氧化和杀虫作用. 进一步的分析显示了15种化合物,包括类化合物,支持传统的兽医用途.
科学领域:
- 植物化学 植物化学
- 兽医寄生虫学 兽医寄生虫学
- 自然产品化学 自然产品化学
背景情况:
- 药用植物正在探索对抗耐药性疾病的天然疗法.
- 传统上,Mitragyna inermis 叶片提取物在兽医中用于治疗小反动物的胃肠病.
研究的目的:
- 为了评估Mitragyna inermis提取物和分片的抗氧化剂,甲虫和幼虫毒性.
- 使用UPLC-QToF-ESI-MS. 在最强的提取物中识别活性化合物.
主要方法:
- 制备了水性和乙醇提取物,以及六,二甲和乙醇部分.
- 使用DPPH激素清除和铁离子还原试验来评估抗氧化活性.
- 评估了对Haemonchus contortus成年虫和幼虫的虫活动.
- 使用Artemia salina进行了虫毒性测试.
- 使用超高性能液态染色学加上四极点飞行时间电喷射电离质谱法 (UPLC-QToF-ESI-MS) 进行化学分析.
主要成果:
- 这两种提取物都表现出显著的抗氧化活性,对Artemia salina幼虫无毒 (CL50 > 0.1μg/mL).
- 提取物有效地降低了Haemonchus contortus成年的幼虫迁移和运动能力 (p < 0.001).
- 分数显示活性较低,除了对成年的六分数外,这表明化合物具有协同作用.
结论:
- 米特拉基纳内尔米斯 (Mitragyna inermis) 具有显著的除草剂和抗氧化剂特性.
- 这些发现支持传统的兽医使用Mitragyna inermis治疗胃肠道强力菌.
- 确定的化合物之间的协同相互作用,包括7种类化合物,可能有助于观察到的虫杀虫疗效.
更多相关视频
08:31Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine
Published on: October 11, 2019
10.3K
08:56Detection of Regulated Ergot Alkaloids in Food Matrices by Liquid Chromatography-Trapped Ion Mobility Spectrometry-Time-of-Flight Mass Spectrometry
Published on: November 22, 2024
694
相关概念视频
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...